MedPath
Found 34 clinical trials|View Analysis
Sort by:

Universal CAR-T Cells (REVO-UWD-19) for Refractory and Relapsed B-Cell Tumors

Early Phase 1
Recruiting
Conditions
B Cell Lymphoma
B Cell Leukemia
B Cell Malignancy
Interventions
Biological: Single dose injection of certain dose of UWD-19
First Posted Date
2024-10-28
Last Posted Date
2024-11-01
Lead Sponsor
Wondercel Biotech (ShenZhen)
Target Recruit Count
30
Registration Number
NCT06662227
Locations
🇨🇳

The First Affiliated Hospital of University of Science and Technology of China, Hefei, Anhui, China

A Study to Investigate Safety and Effectiveness of BGB-16673 in Combination With Other Agents in Participants With Relapsed or Refractory B-Cell Malignancies

Phase 1
Recruiting
Conditions
B-cell Malignancy
Relapsed Cancer
Refractory Cancer
B-cell Lymphoma
Interventions
Drug: BGB-16673
Drug: sonrotoclax
Drug: Zanubrutinib
First Posted Date
2024-10-10
Last Posted Date
2024-12-16
Lead Sponsor
BeiGene
Target Recruit Count
170
Registration Number
NCT06634589
Locations
🇺🇸

Mayo Clinic Jacksonville, Jacksonville, Florida, United States

🇺🇸

Moffitt Cancer Center, Tampa, Florida, United States

🇺🇸

University of Michigan Health System, Ann Arbor, Michigan, United States

and more 40 locations

Anti-CD19-CAR-T Cells in Subjects With Relapsed/Refractory B Cell Malignancies

Early Phase 1
Recruiting
Conditions
B-Cell Malignancy
Interventions
Genetic: Anti-CD19-CAR-T cells
Drug: Fludarabine
Drug: Cyclophosphamide
First Posted Date
2024-08-01
Last Posted Date
2024-08-01
Lead Sponsor
Shanghai First Song Biotechnology Co., LTD
Target Recruit Count
9
Registration Number
NCT06532630
Locations
🇨🇳

The First Affiliated Hospital of Anhui Medical University, Hefei, Anhui, China

A Safety and Efficacy Study Evaluating CTX112 in Subjects With Relapsed or Refractory B-Cell Malignancies

Phase 1
Recruiting
Conditions
B-cell Lymphoma
Large B-cell Lymphoma
B-cell Malignancy
Mantle Cell Lymphoma
Marginal Zone Lymphoma
Non-Hodgkin Lymphoma
Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)
Follicular Lymphoma
Interventions
Biological: CTX112
First Posted Date
2022-12-09
Last Posted Date
2024-08-28
Lead Sponsor
CRISPR Therapeutics AG
Target Recruit Count
120
Registration Number
NCT05643742
Locations
🇦🇺

Research Site, Nedlands, Western Australia, Australia

AS-1763 in Patients With Previously Treated CLL/SLL or Non-Hodgkin Lymphoma

Phase 1
Recruiting
Conditions
B-cell Malignancy
Chronic Lymphocytic Leukemia
Non-Hodgkin Lymphoma
Waldenstrom Macroglobulinemia
Follicular Lymphoma
Marginal Zone Lymphoma
Small Lymphocytic Lymphoma
Mantle Cell Lymphoma
Interventions
Drug: Docirbrutinib
First Posted Date
2022-11-02
Last Posted Date
2024-11-01
Lead Sponsor
Carna Biosciences, Inc.
Target Recruit Count
110
Registration Number
NCT05602363
Locations
🇺🇸

UC Irvine Health, Orange, California, United States

🇺🇸

Mount Sinai Comprehensive Cancer Center, Miami Beach, Florida, United States

🇺🇸

Moffitt Cancer Center, Tampa, Florida, United States

and more 6 locations

Treatment of Chinese Participants With B-Cell Malignancies With BGB-16673, a Bruton Tyrosine Kinase-Targeted Protein-Degrader

Phase 1
Recruiting
Conditions
Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Waldenström Macroglobulinemia
Follicular Lymphoma
Non-Hodgkin Lymphoma
Marginal Zone Lymphoma
Mantle Cell Lymphoma
B-cell Malignancy
Richter's Transformation
DLBCL Unclassifiable
Interventions
Drug: BGB-16673
First Posted Date
2022-03-24
Last Posted Date
2024-12-18
Lead Sponsor
BeiGene
Target Recruit Count
127
Registration Number
NCT05294731
Locations
🇨🇳

Xiangyang Central Hospital, Xiangyang, Hubei, China

🇨🇳

The First Affiliated Hospital of Bengbu Medical University, Bengbu, Anhui, China

🇨🇳

Anhui Provincial Hospital, Hefei, Anhui, China

and more 27 locations

Safety and Clinical Activity of ThisCART22 in Patients With r/r Non-Hodgkin's B Cell Lymphoma

Phase 1
Recruiting
Conditions
B-cell Malignancy
Interventions
Biological: ThisCART22 cells
First Posted Date
2021-11-04
Last Posted Date
2021-11-11
Lead Sponsor
Fundamenta Therapeutics, Ltd.
Target Recruit Count
20
Registration Number
NCT05106946
Locations
🇨🇳

The Affiliated Hospital of Xuzhou Medical University, Xuzhou, Jiangsu, China

Safety and Clinical Activity of ThisCART19 in Patients With r/r Non-Hodgkin's B Cell Lymphoma

Phase 1
Recruiting
Conditions
B-cell Malignancy
Interventions
Biological: ThisCART19 cells
First Posted Date
2021-11-04
Last Posted Date
2021-11-04
Lead Sponsor
Fundamenta Therapeutics, Ltd.
Target Recruit Count
20
Registration Number
NCT05106907
Locations
🇨🇳

The Affiliated Hospital of Xuzhou Medical University, Xuzhou, Jiangsu, China

A Dose-Escalation and Expansion Study of BGB-16673 in Participants With B-Cell Malignancies

Phase 1
Recruiting
Conditions
Marginal Zone Lymphoma
Chronic Lymphocytic Leukemia
Diffuse Large B Cell Lymphoma
B-cell Malignancy
Small Lymphocytic Lymphoma
Follicular Lymphoma
Waldenström Macroglobulinemia
Non-Hodgkin Lymphoma
Mantle Cell Lymphoma
Interventions
Drug: BGB-16673
First Posted Date
2021-08-16
Last Posted Date
2024-12-18
Lead Sponsor
BeiGene
Target Recruit Count
621
Registration Number
NCT05006716
Locations
🇺🇸

Western Regional Medical Center, Llc, Goodyear, Arizona, United States

🇺🇸

Honor Health Research Institute, Scottsdale, Arizona, United States

🇺🇸

Mount Sinai Comprehensive Cancer Center, Miami Beach, Florida, United States

and more 115 locations

A Study of ET-02 in Patients With Relapsed or Refractory B-cell Malignancy(NHL/ALL)

Not Applicable
Active, not recruiting
Conditions
Relapsed or Refractory B-cell Malignancy(NHL/ALL)
Interventions
Biological: ET-02
First Posted Date
2021-06-22
Last Posted Date
2023-02-17
Lead Sponsor
EdiGene (GuangZhou) Inc.
Target Recruit Count
18
Registration Number
NCT04933825
Locations
🇨🇳

•The First Affiliated Hospital of Henan University of Science and Technology, Luoyang, Henan, China

© Copyright 2025. All Rights Reserved by MedPath